Immunic AG | Finanzwire

BRIEF

published on 11/26/2024 at 12:35, 7 days 6 hours ago

Immunic, Inc. Set to Participate in December Investor Conference

Investor Conference Immunic, Inc. Vidofludimus Calcium Piper Sandler Small Molecule Therapies
PRESS RELEASE

published on 11/26/2024 at 12:30, 7 days 6 hours ago

Immunic, Inc. to Participate in Investor Conference in December
Immunic, Inc. to Participate in Investor Conference in December. Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing therapies for chronic inflammatory and autoimmune diseases, announces participation in Piper Sandler 36th Annual Healthcare Conference in New York

Investor Conference Biotechnology Immunic Inc. Clinical Pipeline Autoimmune Diseases
BRIEF

published on 11/13/2024 at 12:35, 20 days 6 hours ago

Immunic Publishes Phase 1/1b Trial Data of IMU-856 in The Lancet

Clinical Trial Immunic Gastroenterology IMU-856 Celiac Disease
PRESS RELEASE

published on 11/13/2024 at 12:30, 20 days 6 hours ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Immunic announces publication of phase 1/1b clinical trial data of IMU-856 in The Lancet Gastroenterology & Hepatology. Positive results in celiac disease patients. Potential new approach for gastrointestinal diseases

Gastrointestinal Diseases Clinical Trial Immunic IMU-856 Celiac Disease
BRIEF

published on 11/07/2024 at 12:35, 26 days 6 hours ago

Immunic, Inc. Reports Q3 2024 Financial Results

Financial Results Vidofludimus Calcium Phase 3 ENSURE Trials Multiple Sclerosis Research Clinical Trial Updates
PRESS RELEASE

published on 11/07/2024 at 12:30, 26 days 6 hours ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q3 2024 financial results, positive Phase 3 ENSURE Program interim analysis. Twin Phase 3 ENSURE trials and Phase 2 CALLIPER trial on track. Webcast held on Nov 7. IMUX stock update

Financial Results Immunic Inc. Q3 2024 Phase 3 ENSURE Program IMUX Stock
BRIEF

published on 10/31/2024 at 11:35, 1 month 3 days ago

Immunic, Inc. to Release Q3 2024 Financial Results and Corporate Update

Financial Results Biotechnology Clinical Trials Webcast Immunic
PRESS RELEASE

published on 10/31/2024 at 11:30, 1 month 3 days ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Immunic, Inc. (Nasdaq: IMUX) to release Q3 financial results and corporate update on Nov 7, 2024. Webcast at 8:00 am ET. Company developing therapies for inflammatory and autoimmune diseases. Visit www.imux.com for more info

Financial Results Biotechnology Corporate Update Immunic Inc. Clinical Pipeline
BRIEF

published on 10/29/2024 at 11:35, 1 month 5 days ago

Immunic to Participate in Key Conferences Throughout November

Investors Biotechnology Clinical Trials Conférences Immunic
PRESS RELEASE

published on 10/29/2024 at 11:30, 1 month 5 days ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November
Immunic to participate in industry, scientific, and investor conferences in November 2024, presenting data on IMU-856 for celiac disease. Details on events and presentations available on company website

Clinical Trials Conférences Investor Immunic Scientific

1 2 ... 4

Published on 12/03/2024 at 18:43, 9 minutes ago

CORRECTION FROM SOURCE: MacDonald Mines Announces Letter Of Intent With Canuc Resources Corporation
Published on 12/03/2024 at 18:00, 52 minutes ago

RE Royalties Provides $6.3 Million Financing for a 200 Megawatt Solar Project in Alberta, Canada
Published on 12/03/2024 at 17:45, 1 hour 7 minutes ago

CannapharmaRX Updates on Alberta Facility Progress and International Export Strategy
Published on 12/03/2024 at 16:36, 2 hours 16 minutes ago

Coast2Coast First Aid and Aquatics Celebrates 10 Years Anniversary with 100 Free CPR Training for Marginalized Communities
Published on 12/03/2024 at 16:00, 2 hours 52 minutes ago

Ascend Aesthetic Partners Marks First Year Uniting Top Surgeons in Aesthetic Care Nationwide

View all ACCESSWIRE

Published on 12/03/2024 at 18:45, 7 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 12/03/2024 at 17:55, 57 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/03/2024 at 17:45, 1 hour 7 minutes ago

Kudelski IoT and PUFsecurity Combine IoT Security Strengths to Meet the Challenges of Increasing Global Regulation
Published on 12/03/2024 at 16:41, 2 hours 11 minutes ago

TAKKT AG: Andreas Weishaar appointed as Chief Executive Officer of TAKKT AG
Published on 12/03/2024 at 16:09, 2 hours 43 minutes ago

DWK Deutsche Wasserkraft AG launches cash capital increase with subscription rights offer

View all EQS

Published on 12/03/2024 at 18:00, 52 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 12/03/2024 at 17:48, 1 hour 4 minutes ago

Acquisition of BIO Habitat
Published on 12/03/2024 at 17:46, 1 hour 6 minutes ago

Saint-Gobain cancels 5 million shares
Published on 12/03/2024 at 17:41, 1 hour 11 minutes ago

241203 BENETEAU Housing cession closed
Published on 12/03/2024 at 15:00, 3 hours 52 minutes ago

MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES

View all LES ECHOS COMFI WIRE

News